TS
Travis Steed Barclays Latest Price Targets & Analyst Ratings
| Stock | Price | Price Target |
Upside Downside | Rating | Date | |
|---|---|---|---|---|---|---|
1
Becton Dickinson
BDX
$54.6B
| $190.56 | $261 |
37%
upside
| Overweight |
7 Apr ‘25
5 months ago |
|
2
Penumbra
PEN
$10.8B
| $276.40 | $320 |
16%
upside
| Buy |
14 Mar ‘25
6 months ago |
|
3
Abbott
ABT
$231B
| $132.65 | $150 |
13%
upside
| Buy |
10 Mar ‘25
6 months ago |
|
4
Solventum
SOLV
$12.8B
| $73.79 | $85 |
15%
upside
| Neutral |
26 Feb ‘25
6 months ago |
|
5
Edwards Lifesciences
EW
$45.8B
| $78.01 | $90 |
15%
upside
| Buy |
16 Dec ‘24
8 months ago |
|
|
CBLL
6
CeriBell, Inc. Common Stock
CBLL
$424M
| $11.56 | $32 |
177%
upside
| Buy |
5 Nov ‘24
10 months ago |
|
7
Baxter International
BAX
$12.6B
| $24.49 | $45 |
84%
upside
| Neutral |
5 Mar ‘24
1 year ago |
|
8
Outset Medical
OM
$251M
| $14.15 | $45 |
218%
upside
| Underperform |
13 Oct ‘23
1 year ago |
|
9
Stryker
SYK
$149B
| $388.79 | $315 |
19%
downside
| Buy |
5 Sep ‘23
2 years ago |
|
10
Insulet
PODD
$23.8B
| $337.94 | $295 |
13%
downside
| Buy |
24 Aug ‘23
2 years ago |
|
11
Axogen
AXGN
$773M
| $16.80 | $16 |
5%
downside
| Overweight |
22 Aug ‘23
2 years ago |
|
12
Tandem Diabetes Care
TNDM
$864M
| $12.79 | $33 |
158%
upside
| Underperform |
5 May ‘23
2 years ago |
|
13
Zimmer Biomet
ZBH
$20.7B
| $104.26 | $160 |
53%
upside
| Neutral |
3 May ‘23
2 years ago |
|
14
Intuitive Surgical
ISRG
$163B
| $455.85 | $315 |
31%
downside
| Buy |
19 Apr ‘23
2 years ago |
|
|
15
Becton Dickinson
BDX
$54.6B
| $190.56 | $290 |
52%
upside
| Buy |
3 Jan ‘23
2 years ago |
|
16
Pulmonx
LUNG
$68.9M
| $1.69 | $8 |
373%
upside
| Underperform |
3 Jan ‘23
2 years ago |
|
17
Embecta
EMBC
$895M
| $15.31 | $25 |
63%
upside
| Underperform |
21 Jun ‘22
3 years ago |
|
18
InMode
INMD
$970M
| $15.34 | $85 |
454%
upside
| Overweight |
13 Oct ‘21
3 years ago |
|
|
19
Zimmer Biomet
ZBH
$20.7B
| $104.26 | $180.58 |
73%
upside
| Overweight |
5 Oct ‘21
3 years ago |
|
|
20
Baxter International
BAX
$12.6B
| $24.49 | $100 |
308%
upside
| Overweight |
3 Sep ‘21
4 years ago |
|
|
21
Abbott
ABT
$231B
| $132.65 | $125 |
6%
downside
| Overweight |
2 Jun ‘21
4 years ago |
|
22
DexCom
DXCM
$29.8B
| $76 | $125 |
64%
upside
| Overweight |
25 May ‘21
4 years ago |
|
23
Medtronic
MDT
$121B
| $94.25 | $145 |
54%
upside
| Equal-Weight |
25 May ‘21
4 years ago |
|
24
Boston Scientific
BSX
$155B
| $104.34 | $51 |
51%
downside
| Overweight |
25 May ‘21
4 years ago |
|
|
25
Edwards Lifesciences
EW
$45.8B
| $78.01 | $110 |
41%
upside
| Overweight |
25 May ‘21
4 years ago |
|